Publisheed on Online Journal, by Martha Rosenberg, June 23, 2010.
At a press briefing at the American Psychiatric Association meeting in May in which new research about olfactory reference syndrome (people who think they smell) and links between depression and allergens was presented, a reporter’s pointed question took many aback.
“How do we know your work won’t be used to make bad breath or hay fever mental disorders?” the reporter asked the researchers, whose smiles faded.
The reporter was Daniel Carlat, MD, and his new book, Unhinged, The Trouble with Psychiatry — A Doctor’s Revelations about a Profession in Crisis, continues the shots-across-the-bow to the psychiatric establishment.
Doctors who join pharma speaker bureaus? “Hired guns.”
The Vagus Nerve Stimulator for depression? “A blemish on the reputation of both the FDA and American Psychiatry.”
The popular ADHD diagnosis? “A judgment based on the psychiatrist’s best guess.”
Prescription drug costs? “Neither the patient nor the doctor . . . foots the bill.”
Joseph Biederman, MD’s promotion of Risperdal at Massachusetts General Hospital? “The MGH department of child psychiatry had allowed itself to become a research factory for various drug companies.”
Antidepressant effectiveness? “Only about half — 51 percent — of trials are positive.”
The psychiatric field itself? “Many of the leaders of our field have allowed themselves to become paid puppets of the pharmaceutical industry.”
Unlike industry exposés by former pharma executives, Carlat has not left his field and continues to hold a faculty position at Tufts and see patients. And though he assails psychiatric training and education, research, current practice, biotechnology, turf battles and trends — other fields add knowledge he says; psychiatry adds diseases — anti-psychiatry activists will find him a moderate: He still prescribes the top psychoactive drugs, has taken them himself and even defends the efficacy of electroconvulsive therapy (ECT.)
(In an amusing anecdote in Unhinged, Carlat starts to have a panic attack in a sauna hot light airplane and finds he has no anxiety meds with him. He ends up using cognitive behavioral therapy (CBT) techniques on himself — and they work.)
Because psychiatry deals with non-measurable phenomenon — even the serotonin theory of depression isn’t chemically proved, he writes — it has over embraced the certitude of psychopharmacology to compensate, he says. But do psychiatrists, motivated by mysteries of the human mind and the desire to help people, really want to become mere “pill pushers” whose only contact with patients is 15 minute “med checks” as they hand patients off to less trained professionals for “therapy”?
“If I did therapy exclusively [as opposed to med checks] I would have to take a 40-50 percent pay cut,” Carlat admits in one of many passages that show he is not exempt from the criticism he levels. In fact, many first heard of Carlat in 2007 when his article about promoting the antidepressant Effexor for Wyeth (now Pfizer) for a year, called Dr. Drug Rep, ran in the New York Times magazine.
In an interview, Carlat told me he got less “pushback” from that article than one that ran in the magazine in April, called Mind Over Meds, that provoked another psychiatrist at the American Psychiatric Association (APA) meeting last month to attack him … //
… Why would changing psychiatric training and even who prescribes meds make colleagues uncomfortable? (full text).